Previous 10 | Next 10 |
Moleculin Biotech ( MBRX +0.3% ) announces safety data from two Phase 1 studies, one in the U.S. and one in Europe , evaluating lead drug Annamycin in acute myeloid leukemia (AML) patients. More news on: Moleculin Biotech, Inc., Healthcare stocks news, Read more ... ...
HOUSTON , Feb. 20, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that it has received an independent ass...
VANCOUVER, British Columbia, Feb. 20, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “ Company ” or “ WPD ”), a clinical stage pharmaceutical company is pleased to provide an update on its WP1066 drug in the treatment of pediatric b...
VANCOUVER, British Columbia, Feb. 18, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “ Company ” or “ WPD ”), a clinical stage pharmaceutical company, in collaboration with license partner, Moleculin Biotech, Inc. (“ Moleculi...
HOUSTON , Feb. 18, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, announced the final data from its CTCL clinical trial of WP...
Moleculin Biotech (NASDAQ: MBRX) was featured in a recent Equity Research Report published by ROTH Capital Partners, LLC. The report reads, “Yesterday, MBRX announced the successful conclusion to its open label, single arm U.S. Phase 1 liposomal annamycin trial, having achieved a highly...
Gainers: Unisys (NYSE: UIS ) +44% . More news on: Unisys Corporation, JanOne Inc., Intelsat S.A., Stocks on the move, , Read more ...
Tonix Pharmaceuticals Holding (NASDAQ: TNXP ) -58% on failed Tonmya study . More news on: Tonix Pharmaceuticals Holding Corp., ReWalk Robotics Ltd., Funko, Inc., Stocks on the move, , Read more ...
HOUSTON , Feb. 6, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that it has entered into definitive agre...
February 5, 2020 Palm Beach, FL –February 5, 2020 – Acute Myeloid Leukemia (AML) research has seen great progress with more researchers are now studying the causes, diagnosis, and treatment of Acute myeloid leukemia (AML) at many medical centers, university hospitals, an...
News, Short Squeeze, Breakout and More Instantly...
Moleculin Biotech Inc. Company Name:
MBRX Stock Symbol:
NASDAQ Market:
Moleculin Biotech Inc. Website:
Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML PR Newswire HOUSTON , July 10, 2024 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfoli...
2024-06-17 10:10:00 ET June 17, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the first of a two-part series looking at developments for the treatment of blood cancers. Today's snapshot focuses in on acute myeloid leukemia (AML) and the compan...
Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial PR Newswire – 89% of CRc's were subjects with "poor prognosis" cytogenetics and/or mutations – Current median durability of response (mDOR) of CRc's = 6 months and in...